Stockscreener 앱 받기
6.29
2.02%
-0.13
시장 영업 전:
6.38
0.09
+1.43%
전일 마감가:
$6.42
열려 있는:
$6.44
하루 거래량:
1.44M
Relative Volume:
0.67
시가총액:
$809.49M
수익:
$628.25M
순이익/손실:
$-78.55M
주가수익비율:
-10.15
EPS:
-0.62
순현금흐름:
$-29.73M
1주 성능:
+0.80%
1개월 성능:
-12.40%
6개월 성능:
-57.67%
1년 성능:
-58.29%
1일 변동 폭
$6.27
$6.46
1주일 범위
$6.20
$6.65
52주 변동 폭
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
명칭
Neogenomics Inc
전화
(239) 768-0600
주소
9490 NEOGENOMICS WAY, FORT MYERS, FL
NEO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
6.29 | 826.22M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
478.32 | 179.32B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.48 | 145.22B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
565.19 | 44.23B | 3.93B | 894.97M | 837.70M | 10.82 |
|
IQV
Iqvia Holdings Inc
|
199.17 | 34.14B | 15.50B | 1.33B | 2.16B | 7.34 |
|
A
Agilent Technologies Inc
|
120.18 | 34.19B | 6.63B | 1.17B | 1.19B | 4.05 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-15 | 개시 | Guggenheim | Neutral |
| 2025-04-30 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 개시 | Jefferies | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-08-21 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-02-24 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-02-01 | 업그레이드 | Needham | Hold → Buy |
| 2022-08-26 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-22 | 다운그레이드 | Needham | Buy → Hold |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-03-29 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-29 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 재개 | Stephens | Overweight |
| 2021-12-16 | 개시 | Cowen | Outperform |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-25 | 재개 | Needham | Buy |
| 2021-02-25 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-12-11 | 재개 | BTIG Research | Buy |
| 2020-10-28 | 재확인 | Needham | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-08-28 | 개시 | Guggenheim | Buy |
| 2020-07-29 | 재확인 | Needham | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Buy |
| 2020-04-21 | 재개 | Stephens | Overweight |
| 2020-03-02 | 재개 | Craig Hallum | Buy |
| 2020-02-28 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-01 | 재확인 | Needham | Buy |
| 2019-03-29 | 재확인 | Needham | Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-10-24 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 개시 | Leerink Partners | Outperform |
| 2018-05-02 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2017-08-24 | 개시 | Gabelli & Co | Buy |
| 2016-12-15 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Neogenomics Inc 주식(NEO)의 최신 뉴스
What are the latest earnings results for NeoGenomics Inc.Strong return on assets - jammulinksnews.com
How many analysts rate NeoGenomics Inc. as a “Buy”Maximize gains with professional stock picks - jammulinksnews.com
NeoGenomics (NEO): A Buy-the-Dip Opportunity in Oncology Diagnostics or a Risky Bet? - AInvest
How volatile is NeoGenomics Inc. stock compared to the marketBuild wealth faster with consistent growth stocks - jammulinksnews.com
NeoGenomics (NEO) Reports Q2: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
What are the technical indicators suggesting about NeoGenomics Inc.Maximize your portfolio’s growth potential - jammulinksnews.com
What institutional investors are buying NeoGenomics Inc. stockFastest return on investment - jammulinksnews.com
What is the risk reward ratio of investing in NeoGenomics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com
When is NeoGenomics Inc. stock expected to show significant growthDiscover hidden gems in the stock market - jammulinksnews.com
How strong is NeoGenomics Inc. company’s balance sheetGet timely alerts on market movers - jammulinksnews.com
What is the dividend policy of NeoGenomics Inc. stockFree Buy/Sell Signal Notifications - jammulinksnews.com
What is NeoGenomics Inc. company’s growth strategyFree Consultation - jammulinksnews.com
Is NeoGenomics Inc. stock overvalued or undervaluedBuild a winning portfolio with smart picks - jammulinksnews.com
What drives NeoGenomics Inc. stock priceFree Predictions - PrintWeekIndia
Is NeoGenomics Inc. a good long term investmentRapid profit acceleration - PrintWeekIndia
NeoGenomics Inc. Stock Analysis and ForecastTremendous growth potential - PrintWeekIndia
Will NeoGenomics Inc. stock benefit from AI tech trendsRapid wealth multiplication - jammulinksnews.com
What analysts say about NeoGenomics Inc. stockExceptional trading performance - PrintWeekIndia
NeoGenomics (NEO) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy - Nature
Bank of America Securities Sticks to Their Hold Rating for NeoGenomics (NEO) - The Globe and Mail
Neogenomics Shares Plunge 7.14% Amid Earnings Woes - AInvest
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know - Yahoo Finance
Pathological Examination Market Gaining Momentum in Cancer - openPR.com
NeoGenomics (NASDAQ:NEO investor five-year losses grow to 81% as the stock sheds US$71m this past week - simplywall.st
Why NeoGenomics Inc. stock attracts strong analyst attention200 Percent Profit Outlook - beatles.ru
Q1 Earnings Highlights: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Testing & Diagnostics Services Stocks - Yahoo Finance
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO - ACCESS Newswire
NEO Stock Price and Chart — NASDAQ:NEO - TradingView
Neogenomics Inc (NEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.50%
1.95%
자본화:
|
볼륨(24시간):